Preliminary Final Report
Filed with ASX · · 32 pages · English
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Chimeric Appoints Jennifer Chow as CEO & MD
- IND clearance received from US FDA for CHM 1101
- Chimeric licenses novel solid tumor CAR T therapy from Penn
- Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial
- Appendix 4C - quarterly
Later from Chimeric Therapeutics
- Partnership with OncoBay Clinical to advance CHM 1101
- European patent granted for CLTX technology used in CHM 1101
- First milestone on path to CDH17 CAR t clinical trial
- CLTX CAR t presents positive initial phase 1 clinical data
- CLTX CAR T data shows regional control of tumour recurrence
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics